- February 18, 2020
Tackling unmet needs: new compounds in development for non-functioning pituitary adenomas and rare endocrine diseases
In today’s podcast, we highlight a new company dedicated to the rare endocrine disease world. Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.
- February 18, 2020
Developing Novel Therapies for Central Nervous System Diseases with Brad Margus Cerevance
Brad Margus, CEO, Cerevance talks about discovering and developing novel therapies for central nervous system diseases using the Cerevance powerful NETSseq target discovery platform and their large collection of human brain tissue samples. Brad explains why the brain is such a challenging organ to study and their efforts to understand brain cell loss in such diseases as Parkinson’s and Alzheimer’s.
- February 14, 2020
Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo
For the last year, biopharma veteran Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate, sacituzumab govitecan. Now, she’s signing on with the company full-time as its new chief medical officer.
- February 13, 2020
French Partnership Deploys AI for Antibody Drug Discovery
French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases.
- February 13, 2020
Scynexis completes patient enrollment for women’s health phase 3 study
Jersey City-based Scynexis Inc., a biotechnology company delivering therapies for difficult-to-treat and often life-threatening infections, said Thursday it completed patient enrollment, ahead of schedule, in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection.
- February 12, 2020
Woman of the Week Podcast
Believing in the power of one, Kinnari Patel’s passion around rare disease is leading to unique development programs and awareness campaigns; she is equally passionate about sharing her learnings on the way to the C-suite as a mentor and sponsor.
- February 12, 2020
Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer
Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC tumours, which highly express Trop-2 and represents an unmet need within a highly treated cancer type. The company’s chief commercial officer Brendan Delaney explains the drug’s efficacious mechanism of action in this tumour type, as well as noting its success to date, particularly in tolerability and how Immunomedics is advancing the ADC in other Trop-2-expressing tumours.
- February 11, 2020
Adverum gains on Phase I data showing efficacy for wet AMD gene therapy
Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication.
